Diagnostyka SA 2024 AR2
The report highlights Diagnostyka Group's strong performance in 2024, with revenue increasing by 23.6% to PLN 1.97 billion and recurring EBITDA rising 32.8% to PLN 508.7 million. The Group expanded its network to over 1,150 specimen collection points and performed over 161 million tests, serving more than 25 million patients. Key developments included the completion of a new headquarters in Lodz, expansion into the diagnostic imaging market, and preparation for the launch of Poland's first comprehensive diagnostics clinic under the Longevity+ program. Additionally, the company prepared for its debut on the Warsaw Stock Exchange, which took place in February 2025.
Company: Diagnostyka SA
Sector: Healthcare & social services
Country: Poland
Year: 2024
Type: AR2
Pages: 91
Back to company
Diagnostyka SA
Directors' Report
The report highlights Diagnostyka Group's strong performance in 2024, with revenue increasing by 23.6% to PLN 1.97 billion and recurring EBITDA rising 32.8% to PLN 508.7 million. The Group expanded its network to over 1,150 specimen collection points and performed over 161 million tests, serving more than 25 million patients. Key developments included the completion of a new headquarters in Lodz, expansion into the diagnostic imaging market, and preparation for the launch of Poland's first comprehensive diagnostics clinic under the Longevity+ program. Additionally, the company prepared for its debut on the Warsaw Stock Exchange, which took place in February 2025.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 22, 2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees